A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.
Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback